Sign in

    Frank Takatin • Lake Street Capital Markets

    Frank Takkinen is a Senior Research Analyst specializing in Life Sciences at Lake Street Capital Markets, where he has built a reputation for in-depth coverage of emerging companies. He covers firms such as AngioDynamics and Anteris Technologies, providing rigorous analysis and differentiated investment ideas to institutional investors. Takkinen joined Lake Street as a seasoned sector expert and is recognized for his insightful research, although specific performance rankings and quantitative metrics are not publicly disclosed. He maintains active credentials appropriate for his analyst role and contributes actively to the firm's annual industry conferences.

    Frank Takatin's questions to Elutia Inc (ELUT) leadership

    Frank Takatin's questions to Elutia Inc (ELUT) leadership • Q2 2025

    Question

    Frank Takatin of Lake Street Capital Markets inquired about potential growth bottlenecks for the successful Elupro launch, the two-step regulatory and launch strategy for the new NXT 41 breast reconstruction platform, and the expected timing for upcoming business development announcements.

    Answer

    CEO Randy Mills explained that Elupro's growth is primarily driven by securing hospital VAC approvals, a predictable process, and that initial production constraints have been resolved. He detailed the derisked regulatory strategy for NXT 41, launching the base matrix in 2026 followed by the drug-eluting version in 2027, clarifying it's a new platform distinct from SimpliDerm. Regarding business development, Mills declined to provide a specific timeline, stating the company is focused on achieving the best outcome rather than rushing a deal.

    Ask Fintool Equity Research AI